1) SIGA is clearly not going to declare the income from the BARDA contract until the whole contract is fulfilled. They've said as much.
2) This is pure fiction of the kind that the Delaware Supreme Court reprimanded Parsons for: "PIP's most likely outcome will be to get 50 percent of all revenue streams in the future, but possibly not current or past earnings streams." It comes out of your hat, which is a hat much like the one Parsons tried to wear.
3) The margin on ST-246 is MUCH less -- and thus better -- than 35 percent.
I don't spend much time on this board any more because it is dominated by name-calling jerks. But I wish the best to everyone else. And I'm still very bullish about SIGA's future, especially its Dengue future.
You are in fact wrong. PIP couldn't come up w the necessary finances. Oddly enough, it was in the aborted merger agreement that SIGA promised to negotiate for a product license in good faith. That's one thing that makes the whole PIP lawsuit stink.
Ignore this idiot. He's a short who thinks he can convince people to sell their stock by either writing generalities or by flat out lying. It's about time he joins the other resident annoyances. IGNORE
Go short -- you wrote that "Siga had years ahead of them" -- which is not the best English, is it, Short? Siga's drug is still years ahead of Chimerix's CMX-001 in terms of the smallpox market, which is all that matters on this board.
You keep blasting Siga, which is why I think you are short, and why you're now on ignore. No shareholder would spend so much time knocking his own stock on a public message board.
CMX001 has had positive results in preventing "Cytomegalovirus Disease in Hematopoietic-Cell Transplantation." See their PR.
Oh for God's sake! That is a scurrilous post. Their positive results were this: "CMX001 to Prevent Cytomegalovirus Disease in Hematopoietic-Cell Transplantation." That has nothing to do with smallpox, and nothing to do with CMXR's chances of sharing in further stockpiling of anti-smallpox, and NOTHING TO DO WITH SIGA. SIGA is still years ahead of CMRX in anti-SMALLPOX results. Golong must have goneshort.
From March 29, 2012, add the usual web designations at the beginning
Sec. 303. Additional Authorities. (a) To create, maintain, protect, expand, or restore domestic industrial base capabilities essential for the national defense, the head of each agency engaged in procurement for the national defense is delegated the authority of the President under section 303 of the Act, 50 U.S.C. App. 2093, to make provision for purchases of, or commitments to purchase, an industrial resource or a critical technology item for Government use or resale, and to make provision for the development of production capabilities, and for the increased use of emerging technologies in security program applications, and to enable rapid transition of emerging technologies.
(b) Materials acquired under section 303 of the Act, 50 U.S.C. App. 2093, that exceed the needs of the programs under the Act may be transferred to the National Defense Stockpile, if, in the judgment of the Secretary of Defense as the National Defense Stockpile Manager, such transfers are in the public interest.
That's correct. According to an executive proclamation, the head of the DOD can now just order it on national security grounds. So thank fortune it shouldn't have to go through the Chimerix-vulnerable process of appeals, where Clerici basically stuck a monkey-wrench into the works. (He's not working for Chimerix any more, after the media attack he engineered via the LA Times stung Barda as well as Siga, and made Barda predisposed to sting Chimerix in return.)
See earlier posts
The rest of her article, published on August 28th:
"Assad's use of chemical weapons should serve as a wake-up call on his ability to use highly portable and devastating biological warfare agents. National security echelons in Washington should view this as an important message.
Given Prime Minister Benjamin Netanyahu's remarks this past weekend, Israel knows that use of both chemical and biological weapons by the Assad regime represents a clear and present danger. If Assad is capable of using chemical weapons near Damascus, he is equally as capable of launching biological weapons, which pose a global pandemic threat. After increasing evidence of a mass-casualty chemical weapons attack in Syria, the international community no longer has the luxury of standing by and see what is next on Assad's weapons-of-mass-destruction agenda."
Dr. Jill Bellamy van Aalst is an international expert and former consultant to NATO on biological warfare and threat reduction.
I'd thought she'd dropped off the map, but Jill Bellamy Dekker is back as Jill Bellamy van Aalst. Here is an excerpt from a recent bioterror warning from her written AFTER the Syrian chemical attack in Israel Hayom (on line):
"Given the probable use of chemical weapons by Assad's forces in Jobar, we should be equally concerned about Syria's biological weapon programs, which have the capacity to cause global epidemics. With the exception of Israel, the international community and media seem heedless that Assad would actually release biological warfare agents.
Assad views chemical and biological weapons as two components of his conventional arsenal. Syria has designated and trained military units in the use and deployment of both chemical and biological weapons. Like the late Saddam Hussein, Assad has demonstrated that he will use these unconventional weapons against his own citizens. The international community must now begin to plan for the use of biological warfare Category A agents (anthrax, botulinum toxin, smallpox, plague, tularemia, and viral hemorrhagic fevers such as Ebola), given the significant global impact of such an attack.
Assad's chemical and biological weapons programs are long-term and strategic in nature. The reality of chemical and biological weapons programs is that these are clandestine and Syria's most valued weapon class. The Assad regime has for years designated targets for its chemical weapons. It has also made statements, most recently in July 2012, acknowledging its chemical and biological weapons programs. In 2006, it considered chemical and biological weapons part of its conventional arsenal."
More in next installment
I remember that Jill Dekker described Syria's biological warfare threat in the New English Review at some point. She said she believed they'd been working on smallpox specifically, and very likely strains that would not be subject to existing vaccines. But Siga's antiviral drug would continue to work on whatever strain of orthopox virus.
"...Muallem said Syria had capabilities that would 'surprise' the world,..."
Hmm. Wonder what "capabilities" he's talking about, since they already used chemical weapons?
Of course you can ignore Drod. It works well. The endless ranting and vindictive shouting just goes away.
In my opinion he's not a master of anything, except for posting too much. People like him drove our best poster, Boomer, clean off the board.
SIGA Technologies Inc (SIGA-Outperform): PharmAthene Merges with Theraclone, We Expect Due to Possibility of Re duced Damages from Siga Lawsuit, Reiterate Outperform
Price: $3.23 Price Target: $11.00
PharmAthene announced that it will merge with Theraclone, a private company in a reverse merger transaction. It is an all-stock transaction, with shareholders of each company owning 50% of the new merged entity.
Given the timing of the transaction well before a likely lowering of the damage amount previously awarded by the Delaware Chancery Court indicates to us that PharmAthene is likely admitting limited economic benefit to their shareholders from the Chancery Court.
Next steps in the continuing litigation remain unclear, however we note that in our opinion, time and the law are on the side of SIGA.
Reiterate our OUTPERFORM rating and price target of $11/share. We derive our $11/share price target by determining cash in 12months, and the NPV of the current contract, the potential FDA approval milestone, and the anticipated recurring revenue stream to maintain the SNS at 1.7 million courses of therapy, plus the change in value we would anticipate should SIGA win a second contract to increase the SNS to 8 million courses (reduced by 50% for the risk associated with HHS letting, and SIGA winning this potential contract).